iTBS Can Increase Frontal Dopamine Release in PET Dopamine Imaging.

iTBS Can Increase Frontal Dopamine Release and Improve Glucose Metabolism in PET Dopamine Imaging of Patients With Schizophrenia.

Status

UNKNOWN

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05448430

Enrollment

Registered

2022-07-07

Start date

2022-07-15

Completion date

2024-07-01

Last updated

2022-07-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Schizophrenia

Brief summary

Aim: 1. To confirm that patients with predominant negative symptoms in schizophrenia have deficits in frontal cortical dopamine release when compared with healthy control and patients with positive symptoms. 2\. Our previous study found patients with negative symptoms have more possibilities to have disorders in glucose metabolism, we wonder whether dopamine release, negative symptoms or glucose metabolism can be improved by iTBS. Study design: Case control study.

Detailed description

Eligibility Criteria: Predominant negative symptoms for Positive and Negative Syndrome Scale factor score for negative symptoms of 24 or more, and score of 4 or more on at least two of three core negative PANSS items, PANSS for positive symptoms of 19 or less, HAMD depression scale of 16 or less. Predominant positive symptoms for PANSS for positive symptoms of 20 or more. Healthy control will be recruited matching the age and sex of patient groups, Outcome Measures: Oral glucose tolerance test (OGTT), PET dopamine imaging.

Interventions

DEVICETheta burst stimulation

a new paradigm of high frequency repetitive transcranial magnetic stimulation

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

SCREENING

Masking

DOUBLE (Caregiver, Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to 65 Years

Healthy volunteers

Yes

Inclusion criteria

for negative group * diagnosed with schizophrenia according to ICD-10 or DSM-V * Positive and Negative Syndrome Scale factor score for negative symptoms of 24 or moreand score of 4 or more on at least two of three core negative PANSS items * PANSS for positive symptoms of 19 or less, and HAMD depression scale of 16 or less. * drug-naive Inclusion Criteria for positive group * PANSS for positive symptoms of 20 or more * drug-naive

Exclusion criteria

* drug or alcohol addiction * diagnosed with other major mental disorders according to ICD-10 or DSM-V

Design outcomes

Primary

Measure	Time frame	Description
PET dopamine imaging and OGTT	immediate	PET dopamine imaging and OGTT after iTBS

Countries

China

Contacts

Primary ContactQiongqiong Wu, MD

553733595@qq.com8615084781635

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026